Sustained Therapies

Company Overview

Snapshot

Founded in April 2022, Sustained Therapies operates with 1–10 employees. The company has secured funding across one round from AgChimedes Group to advance its solutions for bacterial and viral diseases.

Business overview

Sustained Therapies is dedicated to reducing the reliance on antibiotics by developing sustainable alternatives for combating bacterial and viral diseases in global livestock production and crop plants. The company's core technology leverages highly specific bacteriophages for bacterial diseases and gene editing/silencing (RNAi) for antiviral solutions. These biopesticide-classified solutions are applicable across poultry, aquaculture, and plants, serving the Agriculture & Food Technologies sector.

Company Intelligence Q&A

What is Sustained Therapies' primary mission?

Sustained Therapies aims to significantly decrease humanity's dependence on antibiotics and create more sustainable methods to combat bacterial and viral diseases in global livestock production and crop plants.

What technologies does Sustained Therapies utilize?

Sustained Therapies develops antibacterial solutions based on highly specific bacteriophages and antiviral solutions using gene editing and silencing (RNAi) technologies.

Which markets does Sustained Therapies target?

Sustained Therapies' solutions are designed for application in poultry, aquaculture, and plants, addressing key bacterial and viral diseases in these areas.

When was Sustained Therapies founded?

Sustained Therapies was founded in April 2022.

What was a key funding event for Sustained Therapies?

In January 2022, Sustained Therapies received funding from AgChimedes Group in a Seed round.